Standardized to the British Research Standard for IgD (code: 67/037) of the National Institute for Biological Standards and Controls (a WHO Laboratory for Biological Standards).

Particle Enhanced Nephelometric Immunoassay (PENIA), for their use on BN™ Series nephelometers of Siemens Healthcare.

Kinetic UDR Non-competitive NIPIA Immunoassay, enhanced with polystyrene particles, for their use on Beckman Coulter's IMMAGE® 800 Immunochemical Systems.

Turbidimetric Immunoassay (TIA), enhanced with polystyrene particles, for their use on Clinical Chemistry automatic analyzers.

Applications available for the most common analyzers of Clinical Chemistry. For example Advia®, Alinity C, AU®, Atellica™, cobas® C, Optilite® or Mindray among others.

Clinical Significance of Immunoglobulin D (IgD)

The main application of serum IgD measurement is in the diagnosis and monitoring of IgD Monoclonal Gammopathies.

IgD myeloma makes up less than 2% of the total, but is generally very aggressive (with reduced survival), often associated with amyloidosis, with high frequency of renal impairment, severe anaemia and extramedullary involvement.

Measurement of IgD level is helpful for follow-up, because usually it is not possible to quantify the monoclonal component by densitometry. It is also helpful in its diagnosis, as an alternative step prior to Immunofixation (IFX), and may prevent an IgD myeloma from being misdiagnosed as a Bence Jones myeloma.

IgD Monoclonal Gammopathies, IgD myeloma, Bence Jones myeloma. WHO code 67/037, BN™ Atellicac Neph Siemens Healthineers, IMMAGE® Beckman Coulter, PENIA, TIA, NIA.